Literature DB >> 9351441

Trophic effect of human pericardial fluid on adult cardiac myocytes. Differential role of fibroblast growth factor-2 and factors related to ventricular hypertrophy.

S Corda1, A Mebazaa, M P Gandolfini, C Fitting, F Marotte, J Peynet, D Charlemagne, J M Cavaillon, D Payen, L Rappaport, J L Samuel.   

Abstract

Pericardial fluid (PF) may contain myocardial growth factors that exert paracrine actions on cardiac myocytes. The aims of this study were (1) to investigate the effects of human PF and serum, collected from patients undergoing cardiac surgery, on the growth of cultured adult rat cardiac myocytes and (2) to relate the growth activity of both fluids to the adaptive changes in overloaded human hearts. Both PF and serum increased the rate of protein synthesis, measured by [14C]phenylalanine incorporation in adult rat cardiomyocytes (PF, +71.9 +/- 8.2% [n = 17]; serum, +14.9 +/- 6.5% [n = 13]; both P < .01 versus control medium). The effects of both PF and serum on cardiomyocyte growth correlated positively with the respective left ventricular (LV) mass. However, the magnitude of change with PF was 3-fold greater than with serum (P < .01). These trophic effects of PF were mimicked by exogenous basic fibroblast growth factor (FGF2) and inhibited by anti-FGF2 antibodies and transforming growth factor-beta (TGF-beta), suggesting a relationship to FGF2. In addition, FGF2 concentration in PF was 20 times greater than in serum. On the other hand, the LV mass-dependent trophic effect, present in both fluids, was independent of FGF2 concentration or other factors, such as angiotensin II, atrial natriuretic factor, and TGF-beta. These data suggest that FGF2 in human PF is a major determining factor in normal myocyte growth, whereas unidentified LV mass-dependent factor(s), present in both PF and serum, participates in the development of ventricular hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351441     DOI: 10.1161/01.res.81.5.679

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  25 in total

Review 1.  Intrapericardial therapy and diagnosis.

Authors:  David H Spodick
Journal:  Curr Cardiol Rep       Date:  2002-01       Impact factor: 2.931

2.  Cyclic stretch induces the release of growth promoting factors from cultured neonatal cardiomyocytes and cardiac fibroblasts.

Authors:  C Ruwhof; A E van Wamel; J M Egas; A van der Laarse
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

3.  FGF23 induces left ventricular hypertrophy.

Authors:  Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

Review 4.  Congenital pericardial defect: report of two cases and literature review.

Authors:  M Montaudon; F Roubertie; F Bire; F Laurent
Journal:  Surg Radiol Anat       Date:  2007-03-22       Impact factor: 1.246

5.  Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2.

Authors:  C Pellieux; A Foletti; G Peduto; J F Aubert; J Nussberger; F Beermann; H R Brunner; T Pedrazzini
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

6.  Fibroblast growth factor-2 mediates pressure-induced hypertrophic response.

Authors:  J E Schultz; S A Witt; M L Nieman; P J Reiser; S J Engle; M Zhou; S A Pawlowski; J N Lorenz; T R Kimball; T Doetschman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

Review 7.  Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease.

Authors:  Armando Luis Negri
Journal:  Int Urol Nephrol       Date:  2013-01-08       Impact factor: 2.370

8.  Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014.

Authors:  Myles Wolf
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-08       Impact factor: 8.237

9.  Progenitor cell therapy in a porcine acute myocardial infarction model induces cardiac hypertrophy, mediated by paracrine secretion of cardiotrophic factors including TGFbeta1.

Authors:  Brendan Doyle; Paul Sorajja; Brian Hynes; Arun H S Kumar; Phillip A Araoz; Paul G Stalboerger; Dylan Miller; Cynthia Reed; Jeffrey Schmeckpeper; Shaohua Wang; Chunsheng Liu; Andre Terzic; David Kruger; Stephen Riederer; Noel M Caplice
Journal:  Stem Cells Dev       Date:  2008-10       Impact factor: 3.272

10.  Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.

Authors:  Erica L Clinkenbeard; Megan L Noonan; Joseph C Thomas; Pu Ni; Julia M Hum; Mohammad Aref; Elizabeth A Swallow; Sharon M Moe; Matthew R Allen; Kenneth E White
Journal:  JCI Insight       Date:  2019-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.